Jefferies analyst Brian Abrahams sees more upside in shares of Alder Biopharmaceuticals following yesterday's 50% rally. He raised his price target for the shares to $62 from $58 saying he feels even more confident in the attractiveness and competitiveness of ALD403's profile after speaking with management. Alder closed yesterday up $8.52 to $25.70. ALD403, a product for migraine prevention, has a more de-risked profile following yesterday's Phase 2b trial data and offers a multi-billion market opportunity, Abrahams tells investors in a research note. He keeps a Buy rating on Alder Biopharmaceuticals.